AbbVie: Balanced Outlook Amid EPS Adjustments and Pipeline ...

Oct 23, 2024 · He has updated the financial model to reflect adjustments in the company’s expected earnings per share (EPS) for the third quarter of 2024, slightly reducing it to align …

CouponFollow Extension

$10.67
OFF

AbbVie Reports Third-Quarter 2024 Financial Results | AbbVie

1 week from now

Oct 30, 2024 · Full-Year 2024 Outlook. AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.67 - $10.87 to $10.90 - $10.94, which includes an unfavorable impact …

abbvie.com

$10.61
OFF

AbbVie Reports Second-Quarter 2024 Financial Results | AbbVie

1 week from now

Jul 25, 2024 · Full-Year 2024 Outlook. AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.61 - $10.81 to $10.71 - $10.91, which includes an unfavorable impact …

abbvie.com

$10.67
OFF

AbbVie Reports Third-Quarter 2024 Financial Results - Nasdaq

1 week from now

Oct 30, 2024 · Full-Year 2024 Outlook. AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.67 - $10.87 to $10.90 - $10.94, which includes an unfavorable impact …

nasdaq.com

8%
OFF

AbbVie Lifts Outlook Again On Immunology Demand; Dividend Raised

1 week from now

Oct 30, 2024 · The announcements came on the heels of an impressive quarterly performance, with AbbVie reporting $3.00 in adjusted EPS on revenue of $14.46B that grew +3.8% Y/Y. The …

seekingalpha.com

$2.95
OFF

AbbVie Lowers Q3 And FY24 Earnings Estimates Amid Higher R&D …

1 week from now

Oct 4, 2024 · AbbVie is set to release its Q3 FY24 results on October 30. The Street expects AbbVie to post adjusted earnings per share of $2.95 on revenue of $14.27 billion. According to …

nasdaq.com

$11.05
OFF

AbbVie Reports Full-Year And Fourth-Quarter 2023 Financial …

1 week from now

Full-Year 2024 Outlook. AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2024 of $11.05 to $11.25. This guidance includes a $0.32 per share dilutive impact related to the …

abbvie.com

$10.70
OFF

AbbVie Reports Full-Year And Fourth-Quarter 2022 Financial Results

1 week from now

Full-Year 2023 Outlook. AbbVie is issuing its adjusted diluted EPS guidance for the full-year 2023 of $10.70 to $11.10. The company's 2023 adjusted diluted EPS guidance excludes any impact …

abbvie.com

$10.57
OFF

AbbVie Reports Second-Quarter 2023 Financial Results

1 week from now

Jul 27, 2023 · Full-Year 2023 Outlook. AbbVie is raising its adjusted diluted EPS guidance for the full year 2023 from $10.57 - $10.97 to $10.90 - $11.10, which includes an unfavorable impact …

abbvie.com

$10.67
OFF

AbbVie Reports Third-Quarter 2024 Financial Results

1 week from now

Oct 30, 2024 · Full-Year 2024 Outlook. AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.67 - $10.87 to $10.90 - $10.94, which includes an unfavorable impact …

abbvie.com

$12.52
OFF

AbbVie Reports Third-Quarter 2021 Financial Results | AbbVie

1 week from now

Oct 29, 2021 · AbbVie is raising its adjusted diluted EPS for the full-year 2021 from $12.52 to $12.62 to $12.63 to $12.67. The company's 2021 adjusted diluted EPS guidance excludes …

abbvie.com

FAQs about AbbVie: Balanced Outlook Amid EPS Adjustments and Pipeline ... Coupon?

What is AbbVie's diluted EPS guidance for the full year 2024?

Full-Year 2024 Outlook AbbVie is raising its adjusted diluted EPS guidance for the full year 2024 from $10.67 - $10.87 to $10.90 - $10.94, which includes an unfavorable impact of $0.64 per share related to acquired IPR&D and milestones expense incurred year-to-date through the third quarter 2024. ...

Why did AbbVie raise its diluted EPS guidance?

Encouraged by the quarter's performance, AbbVie has raised its full-year adjusted diluted EPS guidance from $10.97 - $11.17 to $11.13 - $11.33. This adjustment accounts for the ongoing impact of acquired IPR&D and milestones expense, reflecting management's confidence in the company's operational strength and market strategy. ...

How did AbbVie perform in the third quarter 2024?

NORTH CHICAGO, Ill., Oct. 30, 2024 /PRNewswire/ -- AbbVie (NYSE:ABBV) announced financial results for the third quarter ended September 30, 2024. "We delivered another quarter of strong commercial execution and significant pipeline progress," said Robert A. Michael, chief executive officer, AbbVie. ...

How much did AbbVie (abbv) earn in second quarter?

(RTTNews) - AbbVie (ABBV) announced earnings for second quarter that decreased from last year but beat the Street estimates. The company's earnings came in at $1.370 billion, or $0.77 per share. This compares with $2.024 billion, or $1.14 per share, in last year's second quarter. ...

What is AbbVie's full-year outlook for Skyrizi & Rinvoq?

AbbVie (NYSE: ABBV) has once again raised its full-year outlook on soaring demand for its newer immunology medicines, Skyrizi and Rinvoq. The North Chicago, Illinois-based pharma giant now expects adjusted diluted EPS in the range of $10.90 - $10.94 (consensus: $10.85), up from prior outlook of $10.67 - $10.87. ...

What did AbbVie present at EADV Congress 2024?

At the European Academy of Dermatology and Venerology (EADV) Congress 2024, AbbVie shared more than 30 presentations that showcased the depth and strength of AbbVie 's dermatology portfolio. Presentations highlighted data for Rinvoq (upadacitinib), Skyrizi and lutikizumab across a multitude of dermatological conditions. ...